Which stem cell treatments are established, and which are still experimental
The short answer. FDA Philippines recognizes three widely accepted uses of stem cells: transplantation of blood-forming stem cells, corneal resurfacing with limbal stem cells, and skin regeneration with epidermal stem cells. Any other use is treated as clinical investigation. Before considering an offer, ask which category it belongs to, and expect the answer in writing.
Type “stem cell benefits” into a search bar and you’ll get pages listing dozens of them. The Philippine regulator’s own list of widely accepted applications has three items on it, and it hasn’t grown since 2013.
That gap is the most useful thing a family can understand before anyone pays a deposit. This article explains what the Philippine rules actually say, what “established” and “experimental” mean in practice, and the questions that tell you which side of the line an offer sits on.
It doesn’t tell you whether any treatment is right for you or someone you love. That’s a conversation for the patient’s own doctor.
What counts as an established stem cell treatment in the Philippines?
In August 2013 the Food and Drug Administration issued FDA Circular No. 2013-020, which names three widely accepted stem cell applications:
| Application | What it is, in plain terms |
| Hematopoietic stem cell transplantation | Replacing a patient’s blood-forming cells, using either their own cells or a donor’s. Usually done in tertiary hospitals by specialist teams. |
| Corneal resurfacing with limbal stem cells | Using stem cells from the edge of the cornea to restore the eye’s surface. A specialized eye procedure. |
| Skin regeneration with epidermal stem cells | Using cells from the outer layer of skin to grow new skin, as in some severe burn care. |
FDA officials repeated the same three in 2014, when the agency’s then Director General described them as the acceptable or standard procedures, and again in December 2023, when the agency restated that these were the only accepted stem cell therapies in the country.
The list is short for a reason. Each of these has a long clinical track record, specialist training built around it, and evidence regulators accept as part of ordinary medicine.
What happens to every other use?
The same circular says that research on these products beyond their approved uses is clinical investigation. It has to follow FDA’s clinical trial process under FDA Circular No. 2012-007 and international Good Clinical Practice guidelines.
So in the Philippine framework, “experimental” is a category with rules attached. A use outside the three is something being studied, and studies come with requirements that protect the person taking part.
The DOH sets out several of those requirements in Administrative Order No. 2013-0012, signed in March 2013:
- Stem cell and cell-based therapies may only be performed in facilities the DOH has accredited for them.
- Research and therapies must be approved by an institutional review committee, which is an ethics board that reviews the plan before anyone is treated.
- Informed consent must be obtained from the patient or donor for each procedure.
- Certain preparations, including human embryonic and aborted fetal stem cells, may not be used or promoted at all.
- False claims, including in advertising and marketing, are a violation. Penalties run to suspension or revocation of a facility’s accreditation, without prejudice to criminal action.
In 2014 the FDA’s then Director General said that anyone wanting to offer stem cell treatment beyond the three accepted uses had to register it for either compassionate use or a clinical trial, both of which FDA inspects (Philstar, May 2014).
What does the medical profession’s regulator say?
The Professional Regulatory Board of Medicine, which licenses physicians, issued its own position on stem cell therapy in August 2013. It agreed with the DOH order and stated that stem cell therapy “does not constitute standard care at the present time.”
The Board also agreed that FDA approval is required for several categories, among them genetically altered adult and umbilical cord stem cells, stem cells derived from fat tissue, and live animal stem cells given by injection. It said physicians practicing in this area should have structured, supervised training, and should practice only in DOH-licensed settings such as hospitals and clinics.
Are these rules still current?
Partly, and it’s worth knowing which part is uncertain.
The 2013 framework above is what’s published. In January 2024, after a patient died following treatment at a Quezon City clinic, the Health Secretary announced a review of the 2013 guidelines, including accreditation and licensing. At the time, six facilities held DOH accreditation for stem cell therapy.
The Secretary’s advice to the public at the time was direct: check whether a facility is on the official list, and treat one that isn’t as operating illegally. He noted that most accredited facilities are in large hospitals.
If you read this article months after its review date, check the DOH and FDA pages linked at the end before relying on any detail.
How strong does evidence need to be before something is “established”?
Regulators reach the word “established” slowly, and the reasons are easier to see as a ladder.
| Stage | What it shows | What it doesn’t show |
| Lab and animal studies | That something might be worth testing in people | Anything about what it does in a person |
| Small early studies in people | Whether it can be given without obvious harm, and early signals worth following | Whether it works, or for whom |
| Larger controlled trials | What it does compared with a group that didn’t receive it | Long-term effects, unless the trial ran long enough |
| Repeated trials and long clinical use | A body of evidence strong enough for regulators to treat it as standard care | That it suits every patient |
An offer marketed directly to the public may rest on evidence from the first or second rung, which is normal for a field still being researched. The problem starts when an offer is priced, advertised and described as though it were on the fourth.
You can look up studies being conducted in the country through the Philippine Health Research Registry, a public database of health research and clinical trials run by the Philippine Council for Health Research and Development.
Where do “stem cell” capsules and supplements fit?
Outside both categories.
In December 2023 an FDA director told legislators that no stem cell capsule was registered with the agency. The FDA has also issued public health warnings against unregistered food supplements marketed as oral stem cell therapy, including FDA Advisory No. 2023-2095.
Any product sold as a food supplement may not claim to treat a disease. You can check whether a product is registered at all through the FDA Verification Portal, by registration number or product name.
How do I tell which category an offer falls in?
Five questions settle most of it. A provider offering something legitimate will answer all of them in writing.
- Is this one of the three FDA-recognized applications? If the answer is no, the offer is investigational, and the rest of these questions matter more.
- Is the facility accredited by the DOH for cell-based therapy? A general license to operate is a different document. Ask for the accreditation and check it against the HFSRB’s published register.
- Is the product registered with FDA, or is this part of an FDA-approved trial? Ask for the registration or the trial’s approval details.
- Which ethics committee approved this, and can I see the consent form before I pay anything? AO 2013-0012 requires both review and informed consent.
- What does the patient’s own doctor think? Bring the written answers to that appointment.
Urgency is worth noticing too. Limited slots, a price that expires this month, or a reluctance to put anything in writing are reasons to slow down, whichever category the treatment belongs to.
What this article can’t tell you
It can’t tell you whether any stem cell treatment, established or experimental, is appropriate for a particular person. Experimental doesn’t mean useless, and established doesn’t mean suitable for everyone. Those are judgments for the patient’s own physician, with their full history in front of them.
What a family can do without a medical degree is check the category, check the facility, and ask for the answers in writing. That part is yours.
Frequently asked questions
Which stem cell treatments are recognized in the Philippines?
FDA Circular No. 2013-020 names three widely accepted applications: hematopoietic stem cell transplantation, corneal resurfacing with limbal stem cells, and skin regeneration with epidermal stem cells. FDA restated the same three in 2023.
Is stem cell therapy legal in the Philippines?
It’s regulated. Under DOH Administrative Order No. 2013-0012, stem cell and cell-based therapies may only be performed in DOH-accredited facilities, with ethics committee approval and informed consent. Uses outside the three recognized applications are treated as clinical investigation under FDA rules.
What does “experimental” mean for a stem cell treatment?
It means the treatment is still being studied, and the evidence isn’t yet strong enough for regulators to treat it as standard care. In the Philippine framework, it should be offered within FDA’s clinical trial or compassionate use processes, with ethics review and consent.
Are stem cell capsules the same as stem cell therapy?
No. In December 2023 FDA stated that no stem cell capsule was registered with the agency, and it has warned the public against unregistered supplements marketed as oral stem cell therapy. Check any product on the FDA Verification Portal.
How do I check whether a facility is accredited?
Ask for its DOH accreditation for cell-based therapy in writing and compare it with the HFSRB’s published register. A general license to operate doesn’t cover these therapies on its own.
Where can I find stem cell studies being done in the Philippines?
The Philippine Health Research Registry, run by PCHRD, is a public database of health research and clinical trials in the country.
